QUEST informs readers of the latest advances in urologic prostate cancer research, especially detection, prevention, and treatment.
This study examined the use of PSMA-PET, an advanced imaging technique, and how its use might improve outcomes for patients with recurring prostate cancer. PSMA-PET is more sensitive and specific than older imaging methods like CT scans and bone…
Researchers compared the cardiovascular risks associated with luteinizing hormone-releasing hormone (LHRH) agonists versus gonadotropin-releasing hormone (GnRH) antagonists in prostate cancer patients undergoing androgen deprivation therapy (ADT). Scientists conducted a retrospective analysis using real-world data from more than 45,000 men with…
This study focused on men with prostate cancer who were at high risk for recurrence. Specifically, the researchers were interested in patients whose prostate-specific antigen (PSA) levels were rising quickly. When PSA levels double quickly, there is a higher risk…
This phase II clinical trial (ARTO trial) examined whether adding stereotactic body radiation therapy (SBRT) to a standard treatment of abiraterone acetate and prednisone (AAP) would help improve outcomes for patients with oligometastatic, castrate- resistant prostate cancer (CRPC). Oligometastatic CRPC…
Researchers sought to determine which factors lead to a shorter time to PSA failure, which is a sign of prostate cancer worsening. Their goal was to identify patients who may need more aggressive treatments and to test specified treatments…
As 2024 drew to a close, I attended the 101st annual meeting of the Clinical Society of Genitourinary Surgeons held at Stanford University. Doctor Carolyn Bertozzi, a guest speaker at the conference and the subject of our Feature QUEST article,…
Kenneth Carwell has lived within a 1-mile area his whole life, but his sphere of influence extends far beyond geographic boundaries. Ken’s educational training is in social work, and his roles and responsibilities throughout his 40-year career focused on…
Is equal access to health care associated with reduced racial and ethnic disparities in outcomes of nonmetastatic castration-resistant prostate cancer? A retrospective cohort study of approximately 13,000 veterans treated in an equal-access healthcare setting was conducted. Patients included in the…
Prostate cancer incidence increased by 3% annually from 2014-2019 after two decades of decline, translating to an additional 99,000 new cases. Future progress in reducing prostate cancer-specific mortality may be curtailed by the rising incidence of prostate cancer which also…
This original investigation aimed at characterizing the long-term outcomes of patients with low-risk prostate cancer (i.e., low-volume and low Gleason grade tumors) receiving active surveillance in a multicenter, protocol-directed cohort. A cohort of over 200 men with favorable-risk prostate cancer…
"*" indicates required fields
